Gilead Sets Price at $3,120 Per Patient With Private Insurance for Coronavirus Drug Remdesivir

Gilead Sciences unveiled the cost of its five-day coronavirus treatment.

On Monday, Gilead Chairman and CEO Daniel O’Day penned an open letter outlining the costs for remdesivir treatments.

The cost will be $2,340 per COVID-19 patient for Medicare and “governments of developed countries,” which equates to approximately $390 per vial. However, a U.S. patient with private health insurance will be charged $3,120 — an estimated minimum of $520 per vial — or up to $5,720 per patient for a longer duration.

However, O’Day insists the prices actually below market value...